A COST-UTILITY ANALYSIS OF DEFERIPRONE COMPARED TO DESFERRIOXAMINE AND DEFERASIROX FOR THE TREATMENT OF CHRONIC IRON OVERLOAD IN PEOPLE WITH THALASSAEMIA: AN ITALIAN ADAPTATION OF THE UK MODEL

被引：0
|
作者：
Meloni, A. [1 ]
Neri, M. G. [1 ]
Bentley, A. [2 ]
Hanif, A. [2 ]
Pepe, A. [1 ]
机构：
[1] Fdn G Monasterio CNR Reg Toscana, CMR Unit, Pisa, Italy
[2] Abacus Int, Bicester, Oxon, England
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P425
引用
收藏
页码：150 / 150
页数：1
相关论文
共 27 条
  • [1] A Cost-Utility Analysis of Deferiprone Compared to Desferrioxamine and Deferasirox for the Treatment of Chronic Myocardial Iron Overload in Thalassemia Patients
    Pepe, Alessia
    Hanif, Aishah
    Bentley, Anthony
    Walker, Roderick
    Frizziero, Ludovica
    Putti, Maria Caterina
    Spasiano, Anna
    Borgna-Pignatti, Caterina
    Maggio, Aurelio
    Neri, Maria Giovanna
    Meloni, Antonella
    BLOOD, 2015, 126 (23)
  • [2] Cost-Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
    Bentley, Anthony
    Gillard, Samantha
    Spino, Michael
    Connelly, John
    Tricta, Fernando
    PHARMACOECONOMICS, 2013, 31 (09) : 807 - 822
  • [3] Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
    Anthony Bentley
    Samantha Gillard
    Michael Spino
    John Connelly
    Fernando Tricta
    PharmacoEconomics, 2013, 31 : 807 - 822
  • [4] Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
    Anthony Bentley
    Samantha Gillard
    Michael Spino
    John Connelly
    Fernando Tricta
    PharmacoEconomics, 2013, 31 : 1185 - 1186
  • [5] LIFETIME COST-UTILITY ANALYSES OF DEFERASIROX IN BETA THALASSAEMIA PATIENTS WITH CHRONIC IRON OVERLOAD: A UK PERSPECTIVE
    Karnon, J.
    Tolley, K.
    Chandiwana, D.
    Vieira, J.
    HAEMATOLOGICA, 2012, 97 : 387 - 387
  • [6] Cost-Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective (vol 31, pg 807, 2013)
    Bentley, Anthony
    Gillard, Samantha
    Spino, Michael
    Connelly, John
    Tricta, Fernando
    PHARMACOECONOMICS, 2013, 31 (12) : 1185 - 1186
  • [7] Lifetime Cost-Utility Analyses of Deferasirox in Beta-Thalassaemia Patients with Chronic Iron Overload A UK Perspective
    Karnon, Jonathan
    Tolley, Keith
    Vieira, Joao
    Chandiwana, David
    CLINICAL DRUG INVESTIGATION, 2012, 32 (12) : 805 - 815
  • [8] Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective
    Alessia Pepe
    Giuseppe Rossi
    Anthony Bentley
    Maria Caterina Putti
    Ludovica Frizziero
    Domenico Giuseppe D’Ascola
    Liana Cuccia
    Anna Spasiano
    Aldo Filosa
    Vincenzo Caruso
    Aishah Hanif
    Antonella Meloni
    Clinical Drug Investigation, 2017, 37 : 453 - 464
  • [9] Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective
    Pepe, Alessia
    Rossi, Giuseppe
    Bentley, Anthony
    Putti, Maria Caterina
    Frizziero, Ludovica
    D'Ascola, Domenico Giuseppe
    Cuccia, Liana
    Spasiano, Anna
    Filosa, Aldo
    Caruso, Vincenzo
    Hanif, Aishah
    Meloni, Antonella
    CLINICAL DRUG INVESTIGATION, 2017, 37 (05) : 453 - 464
  • [10] Lifetime Cost-Utility Analyses of Deferasirox in Beta-Thalassaemia Patients with Chronic Iron OverloadA UK Perspective
    Jonathan Karnon
    Keith Tolley
    Joao Vieira
    David Chandiwana
    Clinical Drug Investigation, 2012, 32 : 805 - 815
123